GlobeNewswire·Nov 10, 2026, 4:30 PM ET

iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update

iBio, Inc. reported first-quarter fiscal 2027 financial results ended September 30, 2026, with revenue of $1.1 million.
The company presented preclinical data showing IBIO-610 combined with semaglutide resulted in 93% fat loss versus 77% for semaglutide alone in non-human primates.
IBIO-610 is expected to reach an IND-equivalent filing by the end of 2026, with first-in-human trials planned for the first half of 2027.
Dosing was completed for the single ascending portion of the Phase 1 trial for IBIO-600, with interim data anticipated in the first quarter of 2027.
The multiple ascending dose portion of the IBIO-600 Phase 1 trial is scheduled to begin in the first quarter of 2027.
Research and development expenses rose to $6.7 million from $3.6 million in the prior year period, driven by clinical trial costs & consultant fees.
General and administrative expenses increased to $2.8 million from $2.5 million, primarily due to higher personnel costs & legal fees.
Cash, cash equivalents, & debt securities totaled $76.7 million as of September 30, 2026.
iBio plans to participate in upcoming conferences including Guggenheim Healthcare Innovation, ObesityWeek 2026, & Piper Sandler Healthcare Conference.